CIK 0001923840
THRD Third Harmonic Bio, Inc.
Insider trading from SEC Form 4. Last filing Aug 14, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Signals
Open-market buys and sells at Third Harmonic Bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 13Weak | Edward R. Conner Chief Medical Officer sell | $32k 2,117 shares | -100% | - | |
| 61Notable | Bvf Partners L P/il other sell | $14M 1,000,000 shares | -43% | - | |
| 14Weak | Edward R. Conner Chief Medical Officer sell | $40k 2,673 shares | -100% | - |
Transactions
The last 32 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 11, 2025 | Michael Gladstone director, owner | JOther Stock Optionderivative | -43,584 | $0.00 | $0 | 0 | Aug 14, 2025 |
| Aug 11, 2025 | Natalie C. Holles CEO | JOther Common Stock | -1,218,836 | - | - | 0 | Aug 14, 2025 |
| Aug 11, 2025 | Mark T Iwicki director | JOther Common Stock | -128,631 | - | - | 0 | Aug 14, 2025 |
| Aug 11, 2025 | Christopher M. Murphy Chief Financial & Bus. Officer | JOther Restricted Stock Unitderivative | -47,500 | $0.00 | $0 | 0 | Aug 14, 2025 |
| Aug 11, 2025 | Hans Martin Seidel director | JOther Common Stock | -85,753 | - | - | 0 | Aug 14, 2025 |
| Aug 11, 2025 | Thomas P Soloway director | JOther Stock Optionderivative | -120,166 | $0.00 | $0 | 0 | Aug 14, 2025 |
| Aug 11, 2025 | David P Bonita director | JOther Common Stock | -5,779,071 | - | - | 0 | Aug 14, 2025 |
| Aug 11, 2025 | David P Bonita director | JOther Stock Optionderivative | -43,584 | $0.00 | $0 | 0 | Aug 14, 2025 |
| Aug 11, 2025 | Natalie C. Holles CEO | JOther Stock Optionderivative | -998,854 | $0.00 | $0 | 0 | Aug 14, 2025 |
| Aug 11, 2025 | Mark T Iwicki director | JOther Stock Optionderivative | -83,296 | $0.00 | $0 | 0 | Aug 14, 2025 |
| Aug 11, 2025 | Hans Martin Seidel director | JOther Stock Optionderivative | -53,090 | $0.00 | $0 | 0 | Aug 14, 2025 |
| Aug 11, 2025 | Natalie C. Holles CEO | JOther Restricted Stock Unitderivative | -50,000 | $0.00 | $0 | 0 | Aug 14, 2025 |
| Jan 15, 2025 | Christopher Dinsmore Chief Scientific Officer | AGrant or award Employee Stock Option (right to buy)derivative | +116,000 | $0.00 | $0 | 116,000 | Jan 17, 2025 |
| Jan 15, 2025 | Natalie C. Holles CEO | AGrant or award Employee Stock Option (right to buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Jan 17, 2025 |
| Jan 15, 2025 | Jennifer Dittman Chief Operating Officer | AGrant or award Employee Stock Option (right to buy)derivative | +92,000 | $0.00 | $0 | 92,000 | Jan 17, 2025 |
| Jan 15, 2025 | Dennis Dean Chief Nonclinical Dev. Officer | AGrant or award Employee Stock Option (right to buy)derivative | +92,000 | $0.00 | $0 | 92,000 | Jan 17, 2025 |
| Jan 15, 2025 | Edward R. Conner Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +132,000 | $0.00 | $0 | 132,000 | Jan 17, 2025 |
| Jan 15, 2025 | Christopher Dinsmore Chief Scientific Officer | AGrant or award Restricted Stock Unitderivative | +14,500 | $0.00 | $0 | 14,500 | Jan 17, 2025 |
| Jan 15, 2025 | Edward R. Conner Chief Medical Officer | AGrant or award Restricted Stock Unitderivative | +16,500 | $0.00 | $0 | 16,500 | Jan 17, 2025 |
| Jan 15, 2025 | Jennifer Dittman Chief Operating Officer | AGrant or award Restricted Stock Unitderivative | +11,500 | $0.00 | $0 | 11,500 | Jan 17, 2025 |
| Jan 15, 2025 | Natalie C. Holles CEO | AGrant or award Restricted Stock Unitderivative | +50,000 | $0.00 | $0 | 50,000 | Jan 17, 2025 |
| Jan 15, 2025 | Dennis Dean Chief Nonclinical Dev. Officer | AGrant or award Restricted Stock Unitderivative | +11,500 | $0.00 | $0 | 11,500 | Jan 17, 2025 |
| Nov 8, 2024 | Edward R. Conner Chief Medical Officer | MOption exercise Common Stock10b5-1 | +2,117 | $4.20 | $8,891 | 2,117 | Nov 12, 2024 |
| Nov 8, 2024 | Edward R. Conner Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -2,117 | $15.00 | $32k | 0 | Nov 12, 2024 |
| Nov 8, 2024 | Edward R. Conner Chief Medical Officer | MOption exercise Employee Option Grant (right to buy)derivative10b5-1 | -2,117 | $0.00 | $0 | 368,918 | Nov 12, 2024 |
| Nov 1, 2024 | Atlas Venture Fund XI, L.P. owner | JOther Common Stock10b5-1 | -515,688 | $0.00 | $0 | 9,798,075 | Nov 5, 2024 |
| Oct 29, 2024 | Bvf Partners L P/il other | SOpen-market sale Common Stock | -538,420 | $14.30 | $7.7M | 1,794,218 | Oct 31, 2024 |
| Oct 29, 2024 | Bvf Partners L P/il other | SOpen-market sale Common Stock | -396,963 | $14.30 | $5.7M | 1,367,257 | Oct 31, 2024 |
| Oct 29, 2024 | Bvf Partners L P/il other | SOpen-market sale Common Stock | -64,617 | $14.30 | $924k | 176,692 | Oct 31, 2024 |
| Oct 28, 2024 | Edward R. Conner Chief Medical Officer | MOption exercise Common Stock10b5-1 | +2,673 | $4.20 | $11k | 2,673 | Oct 30, 2024 |
| Oct 28, 2024 | Edward R. Conner Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -2,673 | $15.00 | $40k | 0 | Oct 30, 2024 |
| Oct 28, 2024 | Edward R. Conner Chief Medical Officer | MOption exercise Employee Option Grant (right to buy)derivative10b5-1 | -2,673 | $0.00 | $0 | 371,035 | Oct 30, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Atlas Venture Fund XI, L.P.owner
- Bvf Partners L P/ilother, owner, director
- David P Bonitadirector, owner
- Edward R. ConnerChief Medical Officer
- Dennis DeanChief Nonclinical Dev. Officer
- Christopher DinsmoreChief Scientific Officer
- Jennifer DittmanChief Operating Officer
- Michael Gladstonedirector, owner
- Natalie C. HollesCEO
- Mark T Iwickiceo, officer, director
- Christopher M. MurphyChief Financial & Bus. Officer
- Hans Martin Seideldirector
- Thomas P Solowaydirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.